Cited by 238Cancer, Hypoxia, and MetabolismPancreatic and Hepatic Oncology ResearchAmino Acid Enzymes and Metabolism

The DOI matches its Crossref record; 59 of the 61 references it cites were found in a registry or an index.

Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer

Open access

Elgogary, Amira, Xu, Qingguo, Poore, Brad, Alt, Jesse, Zimmermann, Sarah C., Zhao, Liang, Fu, Jie, Chen, Baiwei, Xia, Shiyu, Liu, Yanfei, Neisser, Marc, Nguyen, Christopher, Lee, Ramon, Park, Joshua K., Reyes, Juvenal, Hartung, Thomas, Rojas, Camilo, Rais, Rana, Tsukamoto, Takashi, Semenza, Gregg L., Hanes, Justin, Slusher, Barbara S., Le, Anne·2016·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1611406113PMC PMC5018752

Open this paper in CoChat — free account

Abstract

Significance: There are no effective therapies currently available for advanced pancreatic cancer. We show that there are two populations of cancer cells within a pancreatic tumor that require targeting by different metabolic inhibitors for effective tumor control. Rapidly dividing cells use glutamine, and can be effectively killed by administration of a nanoparticle containing an inhibitor of glutamine metabolism. Hypoxic cells, which are slowly dividing cells, metabolize glucose and can be targeted by metformin, a drug used for the treatment of diabetes. Clinical trials are needed to determine whether combination therapy, with drugs that effectively block the metabolism of glutamine and glucose, improves the survival of patients with pancreatic cancer.

Integrity signals

Registry

Crossref · 10.1073/pnas.1611406113

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
HMDB: the Human Metabolome Database
Wishart, D. S., Tzur, D., Knox, C., Eisner, R., Guo, A. C., Young, N., Cheng, D., Jewell, K., Arndt, D., Sawhney, S., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl923 · Cited by 3,219
From genomics to chemical genomics: new developments in KEGG
Kanehisa, M. I. (2005) · Nucleic Acids Research · doi:10.1093/nar/gkj102 · Cited by 3,126
Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction
Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
Le, A., Cooper, C. R., Gouw, A. M., Dinavahi, R., Maitra, A., Deck, L. M., Royer, R. E., Jagt, D. L. V., Semenza, G. L., & Dang, C. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914433107 · Cited by 1,528
Self-citation
Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399
Reactome: a knowledgebase of biological pathways
Joshi-Tope, G. (2004) · Nucleic Acids Research · doi:10.1093/nar/gki072 · Cited by 1,291

Show all 61 references

Sorted by citations

Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Metabolism of Amino Acids in Cancer
Wei, Z. C., Liu, X., Cheng, C., Yu, W., & Yi, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.603837 · Cited by 456
Targeting hypoxic tumor microenvironment in pancreatic cancer
Tao, J., Yang, G., Zhou, W., Qiu, J., Chen, G., Luo, W., Zhao, F., You, L., Zheng, L., Zhang, T., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01030-w · Cited by 431
“Based on these observations, it was proposed that rapidly dividing cells use Gln, while hypoxic cells that are slowly dividing metabolize glucose [62].”
Background
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 484
Mitochondrial copper depletion suppresses triple-negative breast cancer in mice
Cui, L., Gouw, A. M., LaGory, E. L., Guo, S., Attarwala, N., Tang, Y., Qi, J., Chen, Y., Gao, Z., Casey, K. M., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0707-9 · Cited by 347
Self-citation
Targeting mitochondrial metabolism for precision medicine in cancer
Sainero‐Alcolado, L., Liaño-Pons, J., Ruiz-Pérez, M. V., & Arsenian‐Henriksson, M. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01022-y · Cited by 338
“Genetic silencing or the inhibition of glutaminase (GLS) using the allosteric inhibitor BPTES [93] decreases proliferation, induces cell death, and reduces proliferation in cancer cell lines as well as tumor growth in vivo [94, 95].”
Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism
Biancur, D. E., Paulo, J. A., Małachowska, B., Quiles Del Rey, M., Sousa, C. M., Wang, X., Sohn, A. S. W., Chu, G. C., Gygi, S. P., Harper, J. W., et al. (2017) · Nature Communications · doi:10.1038/ncomms15965 · Cited by 315
Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: A review
Thakkar, S., Sharma, D., Kalia, K., & Tekade, R. K. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.09.009 · Cited by 321
Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition
Muir, A., Danai, L. V., Gui, D. Y., Waingarten, C. Y., Lewis, C. A., & Vander Heiden, M. G. (2017) · eLife · doi:10.7554/elife.27713 · Cited by 311
“…into glutamate and downstream metabolites during a presteady state, kinetic labeling period and this method has previously been used to corroborate predicted changes in tumor glutamine utilization (Elgogary et al., 2016; Lane et al., 2015; Tardito et al., 2015; Yuneva et al., 2012) (Figure 5B).”
Method
Gluconeogenesis in Cancer: Function and Regulation of PEPCK, FBPase, and G6Pase
Wang, Z., & Dong, C. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.11.003 · Cited by 300
Metabolic reprogramming in cancer: Mechanisms and therapeutics
Nong, S., Han, X., Yu, X., Qian, Y., Wei, Y., Zhang, T., Tian, K., Shen, K., Yang, J., & Ma, X. (2023) · MedComm · doi:10.1002/mco2.218 · Cited by 313
Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment
Sharifi-Rad, J., Quispe, C., Butnariu, M., Rotariu, L. S., Sytar, O., Sestito, S., Rapposelli, S., Akram, M., Iqbal, M., Krishna, A., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02025-4 · Cited by 290
“For example, nanoparticles with the antidiabetic drug metformin have been shown to be effective in a pancreatic cancer cell population by inhibiting glutamine metabolism [13].”
Background
Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy
Tan, Z., Xiao, L., Tang, M., Bai, F., Li, J., Li, L., Shi, F., Li, N., Li, Y., Du, Q., et al. (2018) · Theranostics · doi:10.7150/thno.21451 · Cited by 279
“Integrative metabolomics analysis was applied to discover the adaptive nutrients usage and specific metabolic pathway-addition in metformin-tolerant ovarian cancer and KRASablation-resistant pancreatic cancer [68-70].”
Method
Amino Acid Depletion Therapies: Starving Cancer Cells to Death
Butler, M., van der Meer, L. T., & van Leeuwen, F. N. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.03.003 · Cited by 277
“To increase the half-life and reduce immunogenicity, therapeutic enzymes have been modified by conjugation to polyethylene glycol (PEG) [96], nanoparticle encapsulation [78], or erythrocyte encapsulation [97], and the treatment can be combined with immune-suppressive agents such as prednisone and dexamethasone.”
Background
Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway
Li, B., Cao, Y., Meng, G., Qian, L., Xu, T., Yan, C., Luo, O., Wang, S., Wei, J., Ding, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.11.063 · Cited by 245
Glutamine Metabolism in Cancer
Li, T., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_2 · Cited by 242
Self-citation
We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of6-Diazo-5-oxo-L-norleucine
Lemberg, K. M., Vornov, J. J., Rais, R., & Slusher, B. S. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1148 · Cited by 234
“2A) were designed to introduce bulky hydrophobic groups to enhance the cLogP and cellular permeability of DON, while maintaining plasma stability such that the peripheral exposure to DON would be limited (11, 58).”
BackgroundSelf-citation
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness
Li, Y., Lih, T. M., Dhanasekaran, S. M., Mannan, R., Chen, L., Cieslik, M. P., Wu, Y., Lu, R. J.-H., Clark, D. J., Kołodziejczak, I., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.12.001 · Cited by 237
Self-citation
Glucose Metabolism in Cancer: The Warburg Effect and Beyond
Bose, S., Zhang, C., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_1 · Cited by 240
Self-citation
Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies
Wang, Z., Liu, F., Fan, N., Zhou, C., Li, D., MacVicar, T., Dong, Q., Bruns, C. J., & Zhao, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.589508 · Cited by 189
“Several inhibitors targeting glycolysis have demonstrated a synergistic effect with glutaminase inhibitor, such as metformin (115, 143, 144), Erlotinib (EGFR inhibitor) (145), MLN128 (mTOR inhibitor) (52), and Glutor (glucose uptake inhibitor) (146).”
Background
Drug-induced amino acid deprivation as strategy for cancer therapy
Fung, M. K. L., & Chan, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0509-9 · Cited by 172
“Recent development of a novel BPTES formulation, the BPTES nanoparticles (BPTES-NPs) were reported to have anti-tumor activity comparable to CB-839 in an orthotopic pancreatic cancer mouse model [61].”
BackgroundMethodInfluential
Glutaminolysis Promotes Collagen Translation and Stability via α-Ketoglutarate–mediated mTOR Activation and Proline Hydroxylation
Ge, J., Cui, H., Xie, N., Banerjee, S., Guo, S., Dubey, S., Barnes, S., & Liu, G. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0238oc · Cited by 166
“In addition, we applied glutamine deprivation to dampen glutaminolysis and found that, similarly to CB-839 and BPTES, this procedure decreased only collagen I and collagen III in myofibroblasts (Figure 2F).”
Influential
Sirtuin5 contributes to colorectal carcinogenesis by enhancing glutaminolysis in a deglutarylation-dependent manner
Wang, Y.-Q., Wang, H.-L., Xu, J., Tan, J., Fu, L., Wang, J., Zou, T., Sun, D., Gao, Q., Chen, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02951-4 · Cited by 169
Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer
Matés, J. M., Paola, F. J. D., Campos-Sandoval, J. A., Mazurek, S., & Márquez, J. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.012 · Cited by 169
Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells
Sunami, Y., Rebelo, A., & Kleeff, J. H. (2017) · Cancers · doi:10.3390/cancers10010003 · Cited by 157
Targeting hepatic Glutaminase 1 ameliorates Non-Alcoholic Steatohepatitis by restoring Very-Low Density Lipoproteins triglyceride assembly
Simón, J., Núñez-García, M., Fernández-Tussy, P., Barbier-Torres, L., Fernández-Ramos, D., Gómez-Santos, B., Buqué, X., Lopitz-Otsoa, F., Goikoetxea-Usandizaga, N., Serrano-Maciá, M., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.01.013 · Cited by 141
“, 2012), BPTES-loaded polyethylenoglycol nanoparticles, a nanoencapsulation allowing the safe administration of this drug, are currently being tested in pre-clinical mouse models (Elgogary et al., 2016).”
Background
Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer
Eibl, G., Cruz‐Monserrate, Z., Korc, M., Petrov, M. S., Goodarzi, M. O., Fisher, W. E., Habtezion, A., Lugea, A., Pandol, S. J., Hart, P. A., et al. (2017) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2017.07.005 · Cited by 148
MR image-guided delivery of cisplatin-loaded brain-penetrating nanoparticles to invasive glioma with focused ultrasound
Timbie, K. F., Afzal, U., Date, A. A., Zhang, C., Song, J. S., Miller, G. W., Suk, J. S., Hanes, J. S., & Price, R. J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.017 · Cited by 133
Self-citation
5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA -Mutant Colorectal Cancers
Zhao, Y., Feng, X., Chen, Y., Selfridge, J. E., Gorityala, S., Du, Z., Wang, J. M., Hao, Y., Cioffi, G., Conlon, R. A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0600 · Cited by 130
Activation of Piezo1 promotes osteogenic differentiation of aortic valve interstitial cell through YAP-dependent glutaminolysis
Zhong, G., Su, S., Li, J., Zhao, H., Hu, D., Chen, J., Li, S., Lin, Y., Wen, L., Lin, X., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg0478 · Cited by 127
Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells
Pelosi, E., Castelli, G., & Testa, U. (2017) · Biomedicines · doi:10.3390/biomedicines5040065 · Cited by 128
“Furthermore, glutaminase inhibitors sensitize pancreatic cancer cells to PARP-driven cytotoxic effects on PDAC cells [240].”
Background
Transcriptional factor ICER promotes glutaminolysis and the generation of Th17 cells
Kono, M., Yoshida, N., Maeda, K., & Tsokos, G. C. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714717115 · Cited by 121
“At the translational level, Gls1 inhibitors are being considered for the treatment of various cancers in mice (28, 29), and some of them have entered clinical trials (17, 30).”
Background
Glutamine Metabolism in Cancer
Li, T., Copeland, C., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_2 · Cited by 134
Self-citation
GLS1-mediated glutaminolysis unbridled by MALT1 protease promotes psoriasis pathogenesis
Xia, X., Cao, G., Sun, G., Zhu, L., Tian, Y., Song, Y., Guo, C., Wang, X., Zhong, J., Zhou, W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129269 · Cited by 119
“GLS1 inhibitors are being considered for the treatment of various cancers in mice (55, 56), and some of them have entered clinical trials (57, 58).”
Background
Glutaminase 1 Inhibition Reduces Glycolysis and Ameliorates Lupus‐like Disease in MRL / lpr Mice and Experimental Autoimmune Encephalomyelitis
Kono, M., Yoshida, N., Maeda, K., Suárez‐Fueyo, A., Kyttaris, V. C., & Tsokos, G. C. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41019 · Cited by 122
“Gls1 inhibitors have been considered for the treatment of various cancers in mice (23,24), and some of them have entered clinical trials (25,26).”
Background
HIV infection and latency induce a unique metabolic signature in human macrophages
Castellano, P., Prevedel, L., Valdebenito, S., & Eugenín, E. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-39898-5 · Cited by 117
Combination of metformin with chemotherapeutic drugs via different molecular mechanisms
Peng, M., Darko, K. O., Tao, T., Huang, Y., Su, Q., He, C., Yin, T., Liu, Z., & Yang, X. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.005 · Cited by 111
Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer
Nguyen, T. A., Kirsch, B. J., Asaka, R., Nabi, K., Quinones, A., Tan, J., Antonio, M. J., Camelo, F., Li, T., Nguyen, S. A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.036 · Cited by 111
“Lower cell numbers and glutamate concentrations in the shGCPII-KD cells treated with BPTES compared to those in shControl treated with BPTES demonstrate a growth advantage when cells have GCPII to partially compensate for the decrease in glutamate caused by glutaminase inhibition.”
BackgroundMethodInfluentialSelf-citation
Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice
Boysen, G., Jamshidi‐Parsian, A., Davis, M. A., Siegel, E. R., Simecka, C. M., Kore, R. A., Dings, R. P. M., & Griffin, R. J. (2018) · International Journal of Radiation Biology · doi:10.1080/09553002.2018.1558299 · Cited by 107
“To overcome this limitation, Elgogary et al. (2016) demonstrate the improved pharmacokinetics and efficacy of BPTES bound to nanoparticles compared with free BPTES.”
Background
Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma
Qie, S., Yoshida, A., Parnham, S. R., Oleinik, N. V., Beeson, G. C., Beeson, C. C., Öğretmen, B., Bass, A. J., Wong, K., Rustgi, A. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09179-w · Cited by 101
Discovery of IPN60090, a Clinical Stage Selective Glutaminase‑1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties
Soth, M., Le, K., Francesco, M. E. D., Hamilton, M. M., Liu, G., Burke, J. P., Carroll, C. L., Kovacs, J. J., Bardenhagen, J., Bristow, C. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01398 · Cited by 102
Glutaminase-1 (GLS1) inhibition limits metastatic progression in osteosarcoma
Ren, L., Ruiz‐Rodado, V., Dowdy, T., Huang, S., Issaq, S. H., Beck, J. A., Wang, H., Hoang, C. D., Lita, A., Larion, M., et al. (2020) · Cancer & Metabolism · doi:10.1186/s40170-020-0209-8 · Cited by 102
Glutamine Is Required for M1-like Polarization of Macrophages in Response to Mycobacterium tuberculosis Infection
Jiang, Q., Qiu, Y., Kurland, I. J., Drlica, K., Subbian, S., Tyagi, S., & Shi, L. (2022) · mBio · doi:10.1128/mbio.01274-22 · Cited by 98
Glutaminase isoenzymes in the metabolic therapy of cancer
Matés, J. M., Campos-Sandoval, J. A., & Márquez, J. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.007 · Cited by 99
Lessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R. A., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 95
Metabolic heterogeneity and plasticity of glioma stem cells in a mouse glioblastoma model
Shibao, S., Minami, N., Koike, N., Fukui, N., Yoshida, K., Saya, H., & Sampetrean, O. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox170 · Cited by 96
Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity
Chen, Z., Li, D., Xu, N., Fang, J., Yu, Y., Hou, W., Ruan, H., Zhu, P., Ma, R., Lu, S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01198 · Cited by 91
Endothelial Cell Glucose Metabolism and Angiogenesis
Du, W., Ren, L., Hamblin, M. H., & Fan, Y. (2021) · Biomedicines · doi:10.3390/biomedicines9020147 · Cited by 92
“GLS1 6 BPTES CB-839 Osteosarcoma, pancreatic cancer Multiple cancers Preclinical [114,115] Clinical phase I/II [32]”
Background
Targeting GLS1 to cancer therapy through glutamine metabolism
Yu, W., Yang, X., Zhang, Q., Sun, L., Yuan, S., & Xin, Y. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02645-2 · Cited by 86
Nanomaterial-based regulation of redox metabolism for enhancing cancer therapy
Jia, X., Wang, Y., Qiao, Y., Jiang, X., & Li, J. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00404c · Cited by 87
Nanomedomics
Liang, G., Cao, W., Tang, D., Zhang, H., Yu, Y., Ding, J., Karges, J., & Xiao, H. (2024) · ACS Nano · doi:10.1021/acsnano.3c11154 · Cited by 88
Metabolomics in drug research and development: The recent advances in technologies and applications
Pang, H., & Hu, Z. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.021 · Cited by 89
Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells
Halbrook, C. J., Thurston, G., Boyer, S., Anaraki, C., Jiménez, J. A., McCarthy, A., Steele, N. G., Kerk, S. A., Hong, H. S., Lin, L., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00463-1 · Cited by 80
Phytonanotherapy for management of diabetes using green synthesis nanoparticles
Anand, K., Tiloke, C., Naidoo, P., & Chuturgoon, A. A. (2017) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2017.06.028 · Cited by 80
“Taking this into account these investigators combined metformin and the aforementioned nanoparticle therapy together and found a significant reduction in tumour growth (Elgogary et al., 2016).”
Background
The Heterogeneity of Lipid Metabolism in Cancer
Park, J. K., Coffey, N. J., Limoges, A., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_3 · Cited by 80
Self-citation
Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR‐Driven Lung Cancer
Huang, M., Xiong, D., Pan, J., Zhang, Q., Sei, S., Shoemaker, R. H., Lubet, R. A., Montuenga, L. M., Wang, Y., Slusher, B. S., et al. (2022) · Advanced Science · doi:10.1002/advs.202105885 · Cited by 78
Self-citation
Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment
Tarannum, M., & Vivero-Escoto, J. L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114357 · Cited by 77
Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies
Xu, R., Yang, J., Ren, B., Wang, H., Yang, G., Chen, Y., You, L., & Zhao, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.572722 · Cited by 74
Application of metabolomics technologies toward cancer prognosis and therapy
Hoang, G., Udupa, S., & Le, A. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.07.003 · Cited by 73
Self-citation
Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment
Shen, Y., Chen, C., Huang, Y., Evans, E. E., Cheng, C., Chuang, Y.-J., Zhang, C., & Le, A. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.01.006 · Cited by 75
Self-citation
Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials
Bukhari, S. N. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040866 · Cited by 74
Unveiling the veil of lactate in tumor-associated macrophages: a successful strategy for immunometabolic therapy
Tao, H., Zhong, X., Zeng, A., & Song, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1208870 · Cited by 77
Targeting KRAS: from metabolic regulation to cancer treatment
Shi, Y., Zheng, H., Wang, T., Zhou, S., Zhao, S., Li, M., & Cao, B. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02216-3 · Cited by 81
“Another GLS1 inhibitor BPTES also faces challenges; although it shows promising anti-tumor effects against KRAS-mutant pancreatic cancer, its poor water solubility limits its further application [70–73].”
Nanoparticle-Mediated Inhibition of Mitochondrial Glutaminolysis to Amplify Oxidative Stress for Combination Cancer Therapy
Xu, L., Xu, R. F., Saw, P. E., Wu, J., Cheng, S., & Xu, X. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c02073 · Cited by 69
The ‘Achilles Heel’ of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy
Hoerner, C. R., Chen, V. J., & Fan, A. C. (2019) · Kidney Cancer · doi:10.3233/kca-180043 · Cited by 68
“The availability of structural information about these drugs in complex with GLS1 has led to efforts to rationally evolve BPTES into more potent and stable analogues with better solubility.”
Influential
Metabolic heterogeneity in cancer: An overview and therapeutic implications
Yu, T., Gao, W., & Liu, Y. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188421 · Cited by 70
Self-citation
Therapeutic Repurposing of Biguanides in Cancer
Zhao, H., Swanson, K. D., & Zheng, B. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.03.001 · Cited by 69
Metabolic reprogramming and interventions in angiogenesis
Liu, Y., Wu, Z., Li, Y., Chen, Y., Zhao, X., Wu, M., & Xia, Y. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.05.001 · Cited by 70
“In breast cancer and pancreatic cancer, BPTES has efﬁcacy in regulating the metabolism of cancer cells and reducing the tumor growth in mouse model, which is as an irreversible allosteric inhibitor of GLS1 [169,170].”
Self-citation
Inhibition of Karyopherin beta 1 suppresses prostate cancer growth
Yang, J., Guo, Y., Lu, C., Zhang, R., Wang, Y. E., Luo, L., Zhang, Y., Chu, C. H., Wang, K. J., Obbad, S. I., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0745-2 · Cited by 64
Dual regulation of mitochondrial fusion by Parkin–PINK1 and OMA1
Yamada, T., Ikeda, A., Murata, D., Wang, H., Zhang, C., Khare, P., Adachi, Y., Ito, F., Quirós, P. M., Blackshaw, S., et al. (2025) · Nature · doi:10.1038/s41586-025-08590-2 · Cited by 67
Self-citation
Upregulation of the Glutaminase II Pathway Contributes to Glutamate Production upon Glutaminase 1 Inhibition in Pancreatic Cancer
Udupa, S., Nguyen, S. A., Hoang, G., Nguyen, T. A., Quinones, A., Pham, K., Asaka, R., Nguyen, K., Zhang, C., Elgogary, A., et al. (2019) · PROTEOMICS · doi:10.1002/pmic.201800451 · Cited by 62
Self-citation
Bioenergetic Metabolism In Osteoblast Differentiation
Shen, L., Hu, G., & Karner, C. M. (2022) · Current Osteoporosis Reports · doi:10.1007/s11914-022-00721-2 · Cited by 62
Targeting cellular metabolism to reduce head and neck cancer growth
Yang, J., Guo, Y., Seo, W., Zhang, R., Lu, C., Wang, Y. E., Luo, L., Paul, B., Yan, W., Saxena, D. B., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41523-4 · Cited by 64
Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo
Zhao, Y., Zhao, X., Chen, V., Feng, Y., Wang, L., Croniger, C. M., Conlon, R. A., Markowitz, S. D., Fearon, E. R., Puchowicz, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55718-2 · Cited by 61
Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase
Zimmermann, S. C., Duvall, B. R., & Tsukamoto, T. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00327 · Cited by 59
Self-citation
Developing New Cancer Nanomedicines by Repurposing Old Drugs
Yang, B., & Shi, J. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004317 · Cited by 61
The Metabolic Heterogeneity and Flexibility of Cancer Stem Cells
Tanabe, A., & Sahara, H. (2020) · Cancers · doi:10.3390/cancers12102780 · Cited by 61
Enzyme-based autophagy in anti-neoplastic management: From molecular mechanisms to clinical therapeutics
Ajoolabady, A., Aghanejad, A., Bi, Y., Zhang, Y., Aslkhodapasandhukmabad, H., Abhari, A., & Ren, J. T. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188366 · Cited by 57
Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance
Greene, M. K., Johnston, M. C., & Scott, C. J. (2021) · Cancers · doi:10.3390/cancers13246175 · Cited by 59
Controlled release and antioxidant activity of chitosan and β-lactoglobulin complex nanoparticles loaded with epigallocatechin gallate
Dai, W., Ruan, C., Sun, Y., Gao, X., & Liang, J. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.110802 · Cited by 56
LKB1 promotes metabolic flexibility in response to energy stress
Parker, S. J., Svensson, R. U., Divakaruni, A. S., Lefebvre, A. E. Y. T., Murphy, A. N., Shaw, R. J., & Metallo, C. M. (2016) · Metabolic Engineering · doi:10.1016/j.ymben.2016.12.010 · Cited by 54
“Furthermore, a more recent study aimed at improving the pharmacokinetics of BPTES by loading into PLGA-PEG nanoparticles (BPTESNP) reported synergistic effects of BPTES-NP and metformin treatment in orthotopic models of pancreatic cancer (Elgogary et al., 2016).”
Background
Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer
Singleton, D. C., Dechaume, A.-L., Murray, P. M., Katt, W. P., Baguley, B. C., & Leung, E. Y. (2020) · BMC Cancer · doi:10.1186/s12885-020-06885-3 · Cited by 56
The Heterogeneity of Liver Cancer Metabolism
Salazar, J., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_9 · Cited by 57
Self-citation
Co-Delivery of 2-Dg and V9302 Via a Prodrug Micellar Formulation for Synergistic Targeting of Metabolism in Cancer
Luo, Z., Xu, J., Sun, J., Huang, H., Zhang, Z., Ma, W., Wan, Z., Liu, Y., Pardeshi, A., & Li, S. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.01.019 · Cited by 52
“One possible reason is that the complicated metabolic network in cancer provides a mechanism of compensation when one metabolic pathway is inhibited [28, 48].”
BackgroundSelf-citation
Targeting glycolysis for cancer therapy using drug delivery systems
Huang, Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.003 · Cited by 51
Genetically Programmable Vesicles for Enhancing CAR‐T Therapy against Solid Tumors
Li, X., Zhu, T., Wang, R., Chen, J., Tang, L., Huo, W., Huang, X., & Cao, Q. (2023) · Advanced Materials · doi:10.1002/adma.202211138 · Cited by 49
Comprehensive proteogenomic characterization of rare kidney tumors
Li, G. X., Chen, L., Hsiao, Y., Mannan, R., Zhang, Y., Luo, J., Petralia, F., Cho, H., Hosseini, N., Leprevost, F. D. V., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101547 · Cited by 52
Self-citation
Using word embedding technique to efficiently represent protein sequences for identifying substrate specificities of transporters
Nguyen, T., Le, N. Q. K., Ho, Q., Phan, D., & Ou, Y. (2019) · Analytical Biochemistry · doi:10.1016/j.ab.2019.04.011 · Cited by 45
The Metabolic Interplay between Cancer and Other Diseases
Le, A., Udupa, S., & Zhang, C. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.10.012 · Cited by 48
Self-citation
Tumor microenvironment‐regulating nanomedicine design to fight multi‐drug resistant tumors
Xu, Q., Lan, X., Lin, H., Xi, Q., Wang, M., Quan, X., Yao, G., Yu, Z., Wang, Y., & Yu, M. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1842 · Cited by 45
Self-citation
A PD‐L1‐targeting Regulator for Metabolic Reprogramming to Enhance Glutamine Inhibition‐Mediated Synergistic Antitumor Metabolic and Immune Therapy
Jin, X., Zhang, S., Liang, J., Zhang, S. Y., Qin, Y., Huang, Q., Liu, C., & Zhang, X. (2023) · Advanced Materials · doi:10.1002/adma.202309094 · Cited by 44
Glutamine Metabolism: Molecular Regulation, Biological Functions, and Diseases
Kumar, M. A., Baba, S. K., Khan, I. R., Khan, M. S., Husain, F. M., Ahmad, S., Haris, M., Singh, M., Akil, A. A., Macha, M. A., et al. (2025) · MedComm · doi:10.1002/mco2.70120 · Cited by 52
Biomolecular Interaction Assays Identified Dual Inhibitors of Glutaminase and Glutamate Dehydrogenase That Disrupt Mitochondrial Function and Prevent Growth of Cancer Cells
Zhu, M., Fang, J., Zhang, J., Zhang, Z., Xie, J., Yu, Y., Ruan, J. J., Chen, Z., Hou, W., Yang, G., et al. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b03849 · Cited by 44
Self‐Delivery Nanomedicine for Glutamine‐Starvation Enhanced Photodynamic Tumor Therapy
Zhao, L., Chen, S., Zheng, R., Kong, R., Rao, X., Chen, A., Cheng, H. B., Zhang, D., Li, S., & Yu, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202102038 · Cited by 43
Self-citation
Biomimetic Single‐Atom Nanozyme for Dual Starvation‐Enhanced Breast Cancer Immunotherapy
Zhang, N., Ping, W., Xiang, J., Chu, S., Li, D., Ning, S., Zhu, D., Zeng, W., & Xu, Q. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401362 · Cited by 42
Self-citation
Pancreatic Cancer: “A Riddle Wrapped in a Mystery inside an Enigma”
Borazanci, E. H., Dang, C. V., Robey, R. W., Bates, S. E., Chabot, J. A., & Hoff, D. D. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2070 · Cited by 42
“Glutaminase inhibition in combination with metformin, which inhibits mitochondrial function, seems to be synergistic in highly simplified preclinical models (40).”
Background
The Intratumoral Heterogeneity of Cancer Metabolism
Nabi, K., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_10 · Cited by 42
Self-citation
Chitosan nanoparticle-mediated co-delivery of shAtg-5 and gefitinib synergistically promoted the efficacy of chemotherapeutics through the modulation of autophagy
Zheng, Y., Su, C., Zhao, L., & Shi, Y. (2017) · Journal of Nanobiotechnology · doi:10.1186/s12951-017-0261-x · Cited by 40
Self-citation
Metabolic Reprogramming of Cancer by Chemicals that Target Glutaminase Isoenzymes
Matés, J. M., Campos-Sandoval, J. A., Santos-Jiménez, J. D. L., Segura, J. A., Alonso, F. J., & Márquez, J. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190416165004 · Cited by 41
The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective
Brocco, D., Florio, R., Lellis, L. D., Veschi, S., Grassadonia, A., Tinari, N., & Cama, A. (2020) · Cancers · doi:10.3390/cancers12071849 · Cited by 40

Authors: Elgogary, A., Xu, Q., Poore, B., Alt, J., Zimmermann, S. C., Zhao, L., Fu, J., Chen, B., Xia, S., Liu, Y., Neisser, M., Nguyen, C., Lee, R., Park, J. K., Reyes, J., Hartung, T., Rojas, C., Rais, R., Tsukamoto, T., Semenza, G. L., Hanes, J., Slusher, B. S., & Le, A.
Affiliations: Johns Hopkins University (US)
Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205;
ORCID: Xu, Qingguo
Poore, Brad
Alt, Jesse
Zhao, Liang
Fu, Jie
Xia, Shiyu
Liu, Yanfei
Nguyen, Christopher
Park, Joshua K.
Rojas, Camilo
Rais, Rana
Tsukamoto, Takashi
Semenza, Gregg L.
Hanes, Justin
Slusher, Barbara S.
Le, Anne
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2016-08-24
Volume: 113
Issue: 36
Pages: E5328-36
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1611406113
PMC: PMC5018752
OpenAlex: W2515129893
Cited by: 234
References: 61
Citations by year: 2026: 16 · 2025: 20 · 2024: 17 · 2023: 25 · 2022: 24 · 2021: 38 · 2020: 32 · 2019: 19 · 2018: 21 · 2017: 21 · 2016: 1
FWCI: 8.61
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.pnas.org/preview_site/misc/userlicense.xhtml (vor)
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: HHS | NIH | National Cancer Institute (R01-CA193895, R21-CA169757)
HHS | NIH | National Institute on Drug Abuse (R03-DA032470)
HHS | NIH | National Institute of Mental Health (P30-MH075673)
HHS | NIH | National Center for Advancing Translational Sciences (UL1-TR001079)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
Keywords: BPTES, glutaminase inhibition, glutamine metabolism, pancreatic cancer, nanoparticles, drug encapsulation, metformin, combination therapy, tumor metabolic heterogeneity, tumor hypoxia, glycolysis, glycogen synthesis, CB-839, pharmacokinetics, cancer metabolism
MeSH terms: Animals, Antineoplastic Combined Chemotherapy Protocols, Glutaminase, Glutamine, Humans, Metformin, Pancreatic Neoplasms, Sulfides, Thiadiazoles, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, Benzeneacetamides, Cell Line, Tumor, Mice, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks